drug_type
RELEVANT_DRUG
intervention_type
Antibody–drug conjugate (ADC)
drug_description
Investigational antibody–drug conjugate carrying a topoisomerase I inhibitor payload; binds a tumor-associated antigen to deliver the cytotoxin intracellularly, causing DNA single-strand breaks/replication stress and tumor-cell apoptosis (possible bystander effect).
nci_thesaurus_concept_id
C200198
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of an immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) nectin-4 (PVRL4) conjugated, via a cleavable linker, to a topoisomerase-1 inhibitor, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-nectin-4 ADC SHR-A2102 targets and binds to nectin-4 expressed on tumor cells. Upon binding, internalization and linker cleavage, topoisomerase-1 inhibitor is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing nectin-4. Nectin-4 is overexpressed in a variety of cancers, but has a restricted distribution in normal tissue.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Nectin-4–targeted IgG1 antibody–drug conjugate with a cleavable linker delivering a topoisomerase I inhibitor payload; upon antigen binding and internalization, the payload is released to inhibit topoisomerase I, causing DNA single-strand breaks/replication stress, cell-cycle arrest, and apoptosis in nectin-4–expressing tumor cells (with potential bystander effect).
drug_name
SHR-A2102
nct_id_drug_ref
NCT06474468